<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04786106</url>
  </required_header>
  <id_info>
    <org_study_id>CUREPD101</org_study_id>
    <nct_id>NCT04786106</nct_id>
  </id_info>
  <brief_title>Investigation of Surgery, Collagenase, and Restorex for the Improvement of Peyronie's</brief_title>
  <acronym>iSCRIP</acronym>
  <official_title>Comparison of Collagenase Clostridium Histolyticum to Surgery for the Management of Peyronie's Disease: A Randomized Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Charitable Union for the Research and Education of Peyronie's Disease</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Endo Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Charitable Union for the Research and Education of Peyronie's Disease</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare key clinical outcomes of collagenase clostridium&#xD;
      histolyticum injections versus surgery for the management of Peyronie's Disease.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      After eligible patients have been informed about the study protocol and risks and consent&#xD;
      have been given, men will be randomly assigned into either the collagenase clostridium&#xD;
      histolyticum + penile traction therapy (CCH + PTT) group or to the surgery + penile traction&#xD;
      therapy (surgery + PTT) group. Those in the CCH + PTT group will receive the full 4 series of&#xD;
      8 Xiaflex injections with 1-3 days between each set of 2 injections and 6 weeks prior to the&#xD;
      next series. Patients would then use the RestoreX traction device throughout the series to 3&#xD;
      months post-treatment. Those that were assigned the surgery + PTT treatment protocol would&#xD;
      undergo surgery using either penile plication or incision and grafting, depending on the&#xD;
      degree of curvature and erectile function. Traction using RestoreX will also be prescribed to&#xD;
      these men 2-4 weeks post-operatively until 3 months post-treatment. Key clinical outcomes of&#xD;
      both treatment protocols will be compared.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 30, 2020</start_date>
  <completion_date type="Anticipated">February 15, 2027</completion_date>
  <primary_completion_date type="Anticipated">February 15, 2027</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>The curvature and length assessments will be performed without knowledge as to pre-treatment measurements.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Overall satisfaction with treatment</measure>
    <time_frame>1 year</time_frame>
    <description>Answer to SAPS question #1 (How satisfied are you with the effect of your treatment?) to determine overall satisfaction at all time points</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Subjective reporting of erectile dysfunction post treatment</measure>
    <time_frame>1 year</time_frame>
    <description>Comparison of erectile dysfunction complication rates</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Subjective reporting of changes in penile sensation post treatment</measure>
    <time_frame>1 year</time_frame>
    <description>Comparison of changes in penile sensation complication rates</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Subjective reporting of changes in penile length post treatment</measure>
    <time_frame>1 year</time_frame>
    <description>Comparison of perceived changes in penile length complication rates</description>
  </primary_outcome>
  <primary_outcome>
    <measure>International Index of Erectile Function, Erectile Function Domain (IIEF) Scores</measure>
    <time_frame>1 year</time_frame>
    <description>Comparison of IIEF erectile function domain score (Q1-5, 15; min/max 1-30; higher is better)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Peyronie's Disease Questionnaire (PDQ) Scores</measure>
    <time_frame>1 year</time_frame>
    <description>Comparison of PDQ questionnaire scores; Subdomains - psychological and physical (Q1-6; min/max 0-24; lower is better), penile pain (Q7-9; min/max 0-30; lower is better), symptom bother (Q10-15; min/max 0-16; lower is better)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>International Index of Erectile Function (IIEF) Scores</measure>
    <time_frame>1 year</time_frame>
    <description>Comparison of IIEF questionnaire scores-all domains except erectile function (which is a primary endpoint); subdomains: orgasmic function (Q9-10; min/max 0-10; higher is better), sexual desire (Q11-12; min/max 2-10; higher is better), intercourse satisfaction (Q6-8; min/max 0-15; higher is better), overall satisfaction (Q13-14; min/max 2-10; higher is better)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Beck's Depression Inventory (BDI) Scores</measure>
    <time_frame>1 year</time_frame>
    <description>Comparison of BDI questionnaire scores on depression. 21 items (min/max 0-63, lower is better)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Penile Curvature</measure>
    <time_frame>1 year</time_frame>
    <description>Comparison of changes in penile curvature</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective measurements of penile length post treatment (compared to pre-treatment)</measure>
    <time_frame>1 year</time_frame>
    <description>Comparison of changes in penile length</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Interventions required</measure>
    <time_frame>1 year</time_frame>
    <description>Comparison of subsequent interventions required - surgery or CCH injections</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospitalizations</measure>
    <time_frame>1 year</time_frame>
    <description>Number of hospitalizations or ER visits resulting from treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-standardized questionnaire</measure>
    <time_frame>1 year</time_frame>
    <description>Comparison of non-standardized questionnaire responses</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Peyronie's Disease</condition>
  <arm_group>
    <arm_group_label>CCH+PTT</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Men will receive two injections of CCH administered 1-3 days apart, followed by manual modeling and PTT 30-60 min/day as outlined in our prior publication. Approximately 6 weeks later, the next round of injections will be performed until a maximum of 8 injections in total has been administered. PTT will be continued until the 3-month post-treatment visit.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Surgery+PTT</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Men will undergo either penile plication or I&amp;G based on appropriate clinical criteria for either surgery. 2-4 weeks post-operatively (depending on tolerability), the patients will be asked to perform PTT 30-60 minutes daily until the 3-month post-treatment visit.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Collagenase Clostridium Histolyticum 0.9 MG [Xiaflex] (CCH)</intervention_name>
    <description>Men in this cohort would receive the full series of 8 Xiaflex injections: 2 injections separated by 1-3 days, repeated 3 additional times with 6 week breaks between treatments.</description>
    <arm_group_label>CCH+PTT</arm_group_label>
    <other_name>Xiaflex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Penile Plication Surgery</intervention_name>
    <description>Men in this cohort would undergo surgery using either penile plication or incision and grafting. The specific surgery would be selected based on commonly used criteria: plication for curvatures &lt;70 degrees; I&amp;G used for ≥70 degrees or severe hourglass / hinge deformities. However, the specific surgery (plication vs I&amp;G) will ultimately be decided based on the primary investigator's clinical judgment.</description>
    <arm_group_label>Surgery+PTT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Incision and Grafting (I&amp;G) Surgery</intervention_name>
    <description>Men in this cohort would undergo surgery using either penile plication or incision and grafting. The specific surgery would be selected based on commonly used criteria: plication for curvatures &lt;70 degrees; I&amp;G used for ≥70 degrees or severe hourglass / hinge deformities. However, the specific surgery (plication vs I&amp;G) will ultimately be decided based on the primary investigator's clinical judgment.</description>
    <arm_group_label>Surgery+PTT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>RestoreX Penile Traction Device</intervention_name>
    <description>RestoreX is a Class I PTT device developed by PathRight Medical, is registered with the FDA, and has randomized controlled data demonstrating efficacy when used for the treatment of PD.</description>
    <arm_group_label>CCH+PTT</arm_group_label>
    <arm_group_label>Surgery+PTT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Men with PD&#xD;
&#xD;
          -  &gt;18 years old&#xD;
&#xD;
          -  Curvature ≥30 degrees&#xD;
&#xD;
          -  Ability to achieve an erection satisfactory for intercourse with or without PDE5&#xD;
             inhibitors&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior treatment with CCH or surgery&#xD;
&#xD;
          -  Moderate (shadowing) or severe (&gt;1 cm) penile calcification&#xD;
&#xD;
          -  Any contraindications to CCH, PTT, or surgery - as determined by the PI&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Landon Trost, MD</last_name>
    <phone>888-655-0015</phone>
    <email>email@peyronies.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>The Male Fertility and Peyronie's Clinic</name>
      <address>
        <city>Orem</city>
        <state>Utah</state>
        <zip>84057</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Landon Trost, MD</last_name>
      <phone>888-655-0015</phone>
      <email>trost.landon@mfp.clinic</email>
    </contact>
    <investigator>
      <last_name>Benjamin D. Green, Economics/MA</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Holli Burgon</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>February 5, 2021</study_first_submitted>
  <study_first_submitted_qc>March 3, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 8, 2021</study_first_posted>
  <last_update_submitted>March 3, 2021</last_update_submitted>
  <last_update_submitted_qc>March 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>collagenase clostridium histolyticum</keyword>
  <keyword>RestoreX</keyword>
  <keyword>plication</keyword>
  <keyword>incision and grafting</keyword>
  <keyword>surgery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Penile Induration</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>December 11, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/06/NCT04786106/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>December 28, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/06/NCT04786106/ICF_001.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

